Bristol-Myers Squibb Company (NYSE:BMY)

Stock Price: $71.45

+0.24 (0.34%)

Updated Oct 5, 2022 08:00 PM GMT+0000

Featured app

Invest now

68% of retail CFD accounts lose money

Overview

Financials

Statistics

Profile

Chart

Market Cap	152.56B
Revenue	47.14B
Gross Profit	37.31B
Shares Out	2.14B
EPS (ttm)	3.02
PE Ratio	22.9789
Forward PE	9.4834
Dividend Rate (ttm)	1.6086
Dividend Yield	0.0226

Trading Day	Oct 5
Last Price	$71.45
Previous Close	$71.21
Change ($)	0.24
Change (%)	0.34%
Day's Open	70.94
Day's Range	70.665 - 71.795
Day's Volume	6.79M
52 Week Range	52.01 - 80.03

About Bristol-Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

News

Bristol-Myers versus AbbVie stock: Expert picks a side September 13, 2022

Here’s one sector that offers ‘offense, defense, growth and value’ June 28, 2022

Here is Why Turning Point Therapeutics Jumped 110% June 3, 2022

Turning Point Therapeutics shares more than doubled on Friday June 3, 2022

Bristol-Myers Q4 results are out: this is what the report tells us February 4, 2022

Expert opinion: ‘Bristol-Myers is a buy’ January 10, 2022

Bristol-Myers Squibb stock forecast after announcing $15 billion buyback December 16, 2021

Bristol Myers net loss jumps to £7.34 billion in fiscal Q4 February 4, 2021

Bristol Myers to acquire MyoKardia for £10 billion October 5, 2020

AstraZeneca share price: Drugmaker loses ground in oncology compound race March 20, 2015

Quick info

Country

United States

Industry

Pharmaceutical Preparation Manufacturing

Sector

Manufacturing

Employees

30,250

CEO

Giovanni Caforio

Address

430 E 29th St Fl 14
New York
New York
10016-8367

Phone

12125464000

Website

www.bms.com

Ticker Symbol

BMY

Exchange

New York Stock Exchange

Reporting Currency

USD

Bristol-Myers Squibb Company income statements (2022) (USD)

	July 2022
Total Revenue	11.89B
Cost of Revenue	2.72B
Gross Profit	9.17B
Research & Development	2.32B
Selling General & Admin	1.79B
Operating Expense	9.25B
Operating Income	2.64B
Other Income Expense Net	0
EBIT	2.33B
Interest Income	313M
Pretax Income	1.96B
Income Tax	529M
Minority Interest	8M
Net Income	1.42B
Net Income Basic	1.42B

Bristol-Myers Squibb Company income statements (2021) (USD)

	October 2021
Total Revenue	11.62B
Cost of Revenue	2.29B
Gross Profit	9.33B
Research & Development	3.25B
Selling General & Admin	1.79B
Operating Expense	9.88B
Operating Income	1.75B
Other Income Expense Net	0
EBIT	2.21B
Interest Income	328M
Pretax Income	2.16B
Income Tax	605M
Minority Interest	6M
Net Income	1.55B
Net Income Basic	1.55B

Bristol-Myers Squibb Company income statements (2020) (USD)

	August 2020	June 2020	March 2020
Total Revenue	10.13B	10.13B	10.78B
Cost of Revenue	2.70B	5.08B	5.93B
Gross Profit	7.43B	5.05B	4.85B
Research & Development	2.52B	2.48B	2.32B
Selling General & Admin	1.63B	1.63B	1.61B
Operating Expense	9.24B	9.19B	9.85B
Operating Income	891M	0.94B	0.93B
Other Income Expense Net	361M	688M	-1.23B
EBIT	2.07B	0.94B	0.93B
Interest Income	357M	357M	362M
Pretax Income	1.63B	1.63B	-304M
Income Tax	1.71B	1.71B	462M
Minority Interest	5M	5M	9M
Net Income	-85M	-85M	-775M
Net Income Basic	-85M	-85M	-775M

Bristol-Myers Squibb Company income statements (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Total Revenue	7.95B	6.01B	6.27B	5.92B
Cost of Revenue	3.53B	1.79B	1.87B	1.83B
Gross Profit	4.42B	4.22B	4.40B	4.09B
Research & Development	1.99B	1.36B	1.31B	1.30B
Selling General & Admin	1.73B	1.06B	1.08B	1.01B
Operating Expense	7.24B	4.21B	4.26B	4.14B
Operating Income	701M	1.80B	2.02B	1.78B
Other Income Expense Net	-830M	-453M	-242M	196M
EBIT	701M	1.80B	2.02B	1.78B
Interest Income	279M	209M	123M	45M
Pretax Income	-129M	1.35B	1.78B	1.98B
Income Tax	0.93B	-17M	337M	264M
Minority Interest	-4M	13M	7M	5M
Net Income	-1.06B	1.35B	1.43B	1.71B
Net Income Basic	-1.06B	1.35B	1.43B	1.71B

Bristol-Myers Squibb Company income statements (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Total Revenue	5.97B	5.69B	5.70B	5.19B
Cost of Revenue	1.69B	1.65B	1.60B	1.59B
Gross Profit	4.29B	4.04B	4.11B	3.60B
Research & Development	1.36B	1.26B	2.42B	1.23B
Selling General & Admin	1.34B	1.10B	1.13B	0.98B
Operating Expense	4.38B	4.01B	5.15B	3.80B
Operating Income	1.59B	1.68B	559M	1.39B
Other Income Expense Net	-43M	490M	-42M	386M
EBIT	1.59B	1.68B	559M	1.39B
Interest Income	48M	44M	45M	46M
Pretax Income	1.55B	2.17B	517M	1.78B
Income Tax	357M	255M	135M	284M
Minority Interest	-2M	11M	9M	9M
Net Income	1.19B	1.90B	373M	1.49B
Net Income Basic	1.19B	1.90B	373M	1.49B

Bristol-Myers Squibb Company income statements (2017) (USD)

	December 2017	September 2017	June 2017
Total Revenue	5.45B	5.25B	5.14B
Cost of Revenue	1.48B	1.56B	1.39B
Gross Profit	3.97B	3.69B	3.76B
Research & Development	1.39B	1.48B	1.09B
Selling General & Admin	1.30B	1.15B	1.17B
Operating Expense	4.17B	4.19B	3.64B
Operating Income	1.28B	1.06B	1.50B
Other Income Expense Net	-579M	119M	-207M
EBIT	1.28B	1.06B	1.50B
Interest Income	51M	48M	52M
Pretax Income	698M	1.18B	1.30B
Income Tax	3.03B	327M	373M
Minority Interest	-1M	11M	6M
Net Income	-2.33B	845M	0.92B
Net Income Basic	-2.33B	845M	0.92B

Bristol-Myers Squibb Company balance sheet (2022) (USD)

	July 2022
Current Cash	13.27B
Receivables	9.05B
Inventory	2.14B
Current Assets	30.19B
Other Current Assets	5.57B
Short Term Investments	5.57B
Long Term Investments	70.17B
Property/Plant Equipment	5.97B
Good Will	N.A
Intangible Assets	37.69B
Tangible Assets (Net)	-25.54B
Other Assets	1.86B
Total Assets	100.36B
Accounts Payable	2.88B
Other Current Liabilities	13.08B
Total Current Liabilities	20.92B
Total Liabilities	67.76B
Long Term Debt	37.11B
Current Long Term Debt	4.95B
Minority Interest	61M
Common Stock	2.13B
Treasury Stock	-35.29B
Retained Earnings	24.22B
Capital Surplus	N.A
Shareholder Equity	32.60B
Other Liabilities	N.A

Bristol-Myers Squibb Company balance sheet (2021) (USD)

	October 2021
Current Cash	15.66B
Receivables	9.25B
Inventory	2.16B
Current Assets	31.28B
Other Current Assets	4.07B
Short Term Investments	4.07B
Long Term Investments	79.61B
Property/Plant Equipment	5.87B
Good Will	N.A
Intangible Assets	44.93B
Tangible Assets (Net)	-28.24B
Other Assets	1.50B
Total Assets	110.89B
Accounts Payable	2.70B
Other Current Liabilities	13.70B
Total Current Liabilities	21.46B
Total Liabilities	73.68B
Long Term Debt	39.68B
Current Long Term Debt	5.07B
Minority Interest	71M
Common Stock	2.22B
Treasury Stock	-28.57B
Retained Earnings	22.63B
Capital Surplus	N.A
Shareholder Equity	37.21B
Other Liabilities	N.A

Bristol-Myers Squibb Company balance sheet (2020) (USD)

	August 2020	June 2020	March 2020
Current Cash	21.66B	20.02B	15.82B
Receivables	7.86B	6.70B	7.20B
Inventory	2.38B	2.38B	2.84B
Current Assets	34.34B	34.34B	31.85B
Other Current Assets	2.45B	1.29B	1.41B
Short Term Investments	2.45B	1.86B	2.51B
Long Term Investments	93.73B	5.20B	2.96B
Property/Plant Equipment	5.78B	6.48B	6.84B
Good Will	N.A	N.A	N.A
Intangible Assets	59.17B	59.17B	61.67B
Tangible Assets (Net)	-30.66B	-60.07B	-63.07B
Other Assets	1.67B	1.22B	2.91B
Total Assets	128.08B	128.08B	129.29B
Accounts Payable	2.85B	2.85B	3.07B
Other Current Liabilities	15.75B	13.34B	10.17B
Total Current Liabilities	23.42B	23.42B	19.23B
Total Liabilities	78.98B	78.92B	79.31B
Long Term Debt	41.85B	42.56B	43.53B
Current Long Term Debt	4.82B	4.25B	3.26B
Minority Interest	66M	5M	9M
Common Stock	44.74B	2.25B	2.26B
Treasury Stock	-25.65B	25.65B	24.76B
Retained Earnings	31.57B	31.57B	32.67B
Capital Surplus	N.A	44.44B	43.25B
Shareholder Equity	49.09B	49.09B	49.91B
Other Liabilities	N.A	N.A	N.A

Bristol-Myers Squibb Company balance sheet (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Current Cash	12.35B	30.49B	28.40B	7.34B
Receivables	6.48B	4.29B	4.50B	4.65B
Inventory	4.29B	1.19B	1.31B	1.28B
Current Assets	29.35B	40.19B	37.72B	17.09B
Other Current Assets	1.23B	0.95B	1.38B	1.29B
Short Term Investments	3.05B	2.05B	0.95B	1.43B
Long Term Investments	4.56B	1.19B	1.49B	1.36B
Property/Plant Equipment	6.96B	5.33B	5.36B	5.51B
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	63.97B	1B	1B	1.03B
Tangible Assets (Net)	-61.48B	525M	-1.06B	-1.87B
Other Assets	2.11B	1.59B	1.63B	1.91B
Total Assets	129.94B	57.43B	55.16B	34.83B
Accounts Payable	2.45B	1.89B	2.01B	1.98B
Other Current Liabilities	10.86B	7.42B	6.73B	5.92B
Total Current Liabilities	18.30B	10.49B	9.71B	8.84B
Total Liabilities	78.25B	39.68B	39.01B	19.52B
Long Term Debt	44.06B	24.89B	24.95B	6.16B
Current Long Term Debt	2.76B	N.A	N.A	N.A
Minority Interest	-4M	13M	7M	5M
Common Stock	2.23B	1.63B	1.64B	1.64B
Treasury Stock	25.36B	19.87B	19.57B	19.57B
Retained Earnings	34.47B	36.56B	35.87B	35.11B
Capital Surplus	43.71B	2.21B	2.15B	2.10B
Shareholder Equity	51.60B	17.65B	16.05B	15.22B
Other Liabilities	N.A	N.A	N.A	N.A

Bristol-Myers Squibb Company balance sheet (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Current Cash	6.91B	5.41B	5B	5.34B
Receivables	5.07B	4.82B	4.32B	4.37B
Inventory	1.20B	1.28B	1.24B	1.23B
Current Assets	17.16B	14.87B	13.87B	14.65B
Other Current Assets	1.30B	693M	1B	0.97B
Short Term Investments	1.97B	1.42B	1.08B	1.43B
Long Term Investments	1.89B	2.32B	2.40B	2.50B
Property/Plant Equipment	5.03B	5.09B	5.08B	5.06B
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	1.09B	1.11B	1.09B	1.12B
Tangible Assets (Net)	-3.1B	-4.11B	-5.36B	-5.22B
Other Assets	1.89B	2.01B	2B	1.53B
Total Assets	34.99B	33.73B	32.64B	33.08B
Accounts Payable	1.89B	1.77B	1.87B	1.73B
Other Current Liabilities	6.66B	5.95B	5.92B	5.68B
Total Current Liabilities	10.65B	9.69B	9.88B	9.62B
Total Liabilities	20.86B	19.98B	20.22B	20.18B
Long Term Debt	5.65B	5.69B	5.67B	5.78B
Current Long Term Debt	1.25B	1.25B	1.26B	1.25B
Minority Interest	-2M	11M	9M	9M
Common Stock	1.62B	1.63B	1.63B	1.63B
Treasury Stock	19.57B	19.58B	19.58B	19.43B
Retained Earnings	34.07B	33.29B	32.04B	32.32B
Capital Surplus	2.08B	2.03B	1.97B	1.92B
Shareholder Equity	14.03B	13.64B	12.32B	12.79B
Other Liabilities	N.A	N.A	N.A	N.A

Bristol-Myers Squibb Company balance sheet (2017) (USD)

	December 2017	September 2017	June 2017
Current Cash	5.42B	4.64B	3.47B
Receivables	4.87B	5.21B	5.10B
Inventory	1.17B	1.25B	1.22B
Current Assets	14.85B	15.05B	14.32B
Other Current Assets	1.27B	1.09B	1.14B
Short Term Investments	1.39B	2.48B	3.04B
Long Term Investments	2.55B	2.53B	2.58B
Property/Plant Equipment	5B	5.01B	4.94B
Good Will	N.A	N.A	N.A
Intangible Assets	1.21B	1.21B	1.25B
Tangible Assets (Net)	-6.32B	-3.24B	-3.3B
Other Assets	1.47B	0.97B	883M
Total Assets	33.55B	33.98B	33.41B
Accounts Payable	2.25B	1.70B	1.55B
Other Current Liabilities	6.10B	6.07B	5.87B
Total Current Liabilities	9.56B	9.44B	9.02B
Total Liabilities	21.70B	19.06B	18.59B
Long Term Debt	6.98B	6.98B	6.91B
Current Long Term Debt	N.A	N.A	750M
Minority Interest	-1M	11M	6M
Common Stock	1.63B	1.64B	1.64B
Treasury Stock	19.25B	19B	18.78B
Retained Earnings	31.16B	34.14B	33.93B
Capital Surplus	1.90B	1.85B	1.79B
Shareholder Equity	11.74B	14.78B	14.70B
Other Liabilities	N.A	N.A	N.A

Bristol-Myers Squibb Company cash flow (2022) (USD)

	July 2022
Net Income	1.42B
Depreciation	2.58B
Changes in Receivables	9.05B
Changes in Inventories	2.14B
Cash Change	13.27B
Cash Flow	2.26B
Capital Expenditures	-272M
Investments	N.A
Investing Activity (other)	N.A
Total Investing Cash Flows	-289M
Dividends Paid	N.A
Net Borrowings	23.22B
Other Financing Cash Flows	N.A
Cash Flow Financing	-3.52B
Exchange Rate Effect	N.A

Bristol-Myers Squibb Company cash flow (2021) (USD)

	October 2021
Net Income	1.55B
Depreciation	2.73B
Changes in Receivables	9.25B
Changes in Inventories	2.16B
Cash Change	15.66B
Cash Flow	5.27B
Capital Expenditures	-270M
Investments	N.A
Investing Activity (other)	N.A
Total Investing Cash Flows	-0.98B
Dividends Paid	N.A
Net Borrowings	25.01B
Other Financing Cash Flows	N.A
Cash Flow Financing	-1.78B
Exchange Rate Effect	N.A

Bristol-Myers Squibb Company cash flow (2020) (USD)

	August 2020	June 2020	March 2020
Net Income	-85M	-85M	-775M
Depreciation	5.04B	2.56B	2.48B
Changes in Receivables	-435M	501M	-724M
Changes in Inventories	-452M	642M	1.45B
Cash Change	3.34B	4.12B	3.43B
Cash Flow	8.16B	4.27B	3.89B
Capital Expenditures	-317M	-131M	-186M
Investments	N.A	0.92B	659M
Investing Activity (other)	N.A	N.A	N.A
Total Investing Cash Flows	1.43B	780M	653M
Dividends Paid	N.A	-1.02B	-1.02B
Net Borrowings	22.57B	-48M	26M
Other Financing Cash Flows	N.A	76M	18M
Cash Flow Financing	-2.05B	-0.99B	-1.05B
Exchange Rate Effect	N.A	60M	-67M

Bristol-Myers Squibb Company cash flow (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Net Income	-1.06B	1.35B	1.43B	1.71B
Depreciation	1.24B	171M	169M	170M
Changes in Receivables	-2.19B	214M	142M	421M
Changes in Inventories	470M	-35M	-7M	35M
Cash Change	-17.67B	2.09B	21.07B	424M
Cash Flow	2.04B	2.56B	2.08B	1.39B
Capital Expenditures	-251M	-190M	-191M	-204M
Investments	-0.97B	-1.03B	743M	1.11B
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	-12.04B	491M	715M	1.06B
Dividends Paid	-668M	-671M	-671M	-669M
Net Borrowings	4M	31M	18.94B	-1.32B
Other Financing Cash Flows	-13M	-1M	-2M	-37M
Cash Flow Financing	-7.68B	-0.94B	18.27B	-2.03B
Exchange Rate Effect	6M	-21M	3M	3M

Bristol-Myers Squibb Company cash flow (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Net Income	1.19B	1.90B	373M	1.49B
Depreciation	172M	165M	157M	143M
Changes in Receivables	-251M	-492M	51M	495M
Changes in Inventories	-64M	-30M	-118M	-4M
Cash Change	1.50B	409M	-343M	-79M
Cash Flow	2.43B	1.28B	1.06B	1.18B
Capital Expenditures	-290M	-224M	-198M	-239M
Investments	-317M	-242M	476M	157M
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	-336M	-147M	-348M	-43M
Dividends Paid	-653M	-653M	-654M	-653M
Net Borrowings	74M	-71M	-207M	-344M
Other Financing Cash Flows	1M	4M	-1M	-58M
Cash Flow Financing	-578M	-720M	-1.02B	-1.22B
Exchange Rate Effect	-12M	-3M	-37M	11M

Bristol-Myers Squibb Company cash flow (2017) (USD)

	December 2017	September 2017	June 2017
Net Income	-2.33B	845M	0.92B
Depreciation	197M	188M	211M
Changes in Receivables	341M	-115M	-115M
Changes in Inventories	-36M	65M	13M
Cash Change	777M	1.17B	-440M
Cash Flow	1.12B	1.71B	1.58B
Capital Expenditures	-254M	-262M	-248M
Investments	1.11B	620M	-717M
Investing Activity (other)	N.A	N.A	N.A
Total Investing Cash Flows	1.02B	142M	-1.02B
Dividends Paid	-639M	-640M	-643M
Net Borrowings	-471M	148M	-366M
Other Financing Cash Flows	7M	6M	3M
Cash Flow Financing	-1.35B	-706M	-1.01B
Exchange Rate Effect	-7M	25M	6M

Bristol-Myers Squibb Company dividends (USD)

Ex date	Payment date	Record date	Declared date	Amount	Description	Frequency
30-06-2022	01-08-2022	01-07-2022	N.A	0.54	Ordinary Shares	Quarterly
30-09-2021	01-11-2021	01-10-2021	N.A	0.49	Ordinary Shares	Quarterly
31-12-2020	01-02-2021	04-01-2021	N.A	0.49	Ordinary Shares	Quarterly
01-10-2020	02-11-2020	02-10-2020	N.A	0.45	Ordinary Shares	Quarterly
01-10-2020	02-11-2020	02-10-2020	N.A	0.45	Ordinary Shares	Quarterly
02-07-2020	03-08-2020	06-07-2020	N.A	0.45	Ordinary Shares	Quarterly
02-04-2020	01-05-2020	03-04-2020	N.A	0.45	Ordinary Shares	Quarterly
02-01-2020	03-02-2020	03-01-2020	N.A	0.45	Ordinary Shares	Quarterly
03-10-2019	01-11-2019	04-10-2019	N.A	0.41	Ordinary Shares	Quarterly
03-07-2019	01-08-2019	05-07-2019	N.A	0.41	Ordinary Shares	Quarterly
04-04-2019	01-05-2019	05-04-2019	N.A	0.41	Ordinary Shares	Quarterly
03-01-2019	01-02-2019	04-01-2019	N.A	0.41	Ordinary Shares	Quarterly
04-10-2018	01-11-2018	05-10-2018	N.A	0.40	Ordinary Shares	Quarterly
05-07-2018	01-08-2018	06-07-2018	N.A	0.40	Ordinary Shares	Quarterly
05-04-2018	01-05-2018	06-04-2018	N.A	0.40	Ordinary Shares	Quarterly
04-01-2018	01-02-2018	05-01-2018	N.A	0.40	Ordinary Shares	Quarterly
05-10-2017	01-11-2017	06-10-2017	N.A	0.39	Ordinary Shares	Quarterly
05-07-2017	01-08-2017	07-07-2017	N.A	0.39	Ordinary Shares	Quarterly
05-04-2017	01-05-2017	07-04-2017	N.A	0.39	Ordinary Shares	Quarterly
04-01-2017	01-02-2017	06-01-2017	N.A	0.39	Ordinary Shares	Quarterly
05-10-2016	01-11-2016	07-10-2016	N.A	0.38	Ordinary Shares	Quarterly
29-06-2016	01-08-2016	01-07-2016	N.A	0.38	Ordinary Shares	Quarterly
30-03-2016	02-05-2016	01-04-2016	N.A	0.38	Ordinary Shares	Quarterly
30-12-2015	01-02-2016	04-01-2016	N.A	0.38	Ordinary Shares	Quarterly
30-09-2015	02-11-2015	02-10-2015	N.A	0.37	Ordinary Shares	Quarterly
01-07-2015	03-08-2015	06-07-2015	N.A	0.37	Ordinary Shares	Quarterly